CLAIMS

- A method of treating migraine comprising administering a therapeutic amount of a 1. lidocaine, verapamil, diltiazem, isometheptene, or lisuride condensation aerosol, having an MMAD less than 3 µm and less than 5% lidocaine, verapamil, diltiazem, isometheptene, or lisuride degradation products, to a patient by inhalation, upon activation by the patient of the formation of, and delivery of, the condensation aerosol.
- 2. The method of claim 1, wherein said condensation aerosol is formed by
- a. volatilizing lidocaine, verapamil, diltiazem, isometheptene, or lisuride under conditions effective to produce a heated vapor of the lidocaine, verapamil, diltiazem, isometheptene, or lisuride, and
- b. condensing the heated vapor of the lidocaine, verapamil, diltiazem, isometheptene, or lisuride to form condensation aerosol particles.
- 3. The method according to claim 1, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second.
- 4. The method according to claim 1, wherein said therapeutic amount of lidocaine condensation aerosol comprises between 5 mg and 100 mg of lidocaine delivered in a single inspiration.
- 5. The method according to claim 1, wherein said therapeutic amount of diltiazem condensation aerosol comprises between 2 mg and 50 mg of diltiazem delivered in a single inspiration.
- 6. The method according to claim 1, wherein said therapeutic amount of verapamil condensation aerosol comprises between 0.5 mg and 50 mg of verapamil delivered in a single inspiration.

Express Mail No.: ER 447 856 410 US

7. The method according to claim 1 wherein said therapeutic amount of isometheptene condensation aerosol comprises between 5 mg and 200 mg of isometheptene delivered in a single inspiration.

- 8. The method according to claim 1 wherein said therapeutic amount of lisuride condensation aerosol comprises between 0.1 mg and 1.0 mg of lisuride delivered in a single inspiration.
- 9. The method according to claim 2, wherein said administration results in a peak plasma concentration of said lidocaine, verapamil, diltiazem, isometheptene, or lisuride in less than 0.1 hours.
- 10. The method according to claim 1, wherein at least 50% by weight of the condensation aerosol is amorphous in form.
- 11. A method of administering lidocaine, verapamil, diltiazem, isometheptene, or lisuride to a patient to achieve a peak plasma drug concentration rapidly, comprising administering to the patient by inhalation an aerosol of lidocaine, verapamil, diltiazem, isometheptene, or lisuride having less than 5% lidocaine, verapamil, diltiazem, isometheptene, or lisuride degradation products and an MMAD less than 3 microns wherein the peak plasma drug concentration of lidocaine, verapamil, diltiazem, isometheptene, or lisuride is achieved in less than 0.1 hours.
- 12. A kit for delivering a drug aerosol comprising:
- a) a thin coating of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition, and
 - b) a device for dispensing said thin coating as a condensation aerosol.
- 13. The kit of claim 12, wherein said coating has a thickness of about 5.0 microns.

- 14. The kit of claim 12, wherein the device for dispensing said coating as a condensation aerosol comprises:
 - (a) a flow through enclosure,
- (b) contained within the enclosure, a metal substrate with a foil-like surface and having a thin coating of lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition formed on the substrate surface,
- (c) a power source that can be activated to heat the substrate to a temperature effective to volatilize the lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition contained in said coating, and
- (d) inlet and exit portals through which air can be drawn through said device by inhalation.

wherein heating the substrate by activation of the power source is effective to form a lidocaine, verapamil, diltiazem, isometheptene, or lisuride vapor containing less than 5% lidocaine, verapamil, diltiazem, isometheptene, or lisuride degradation products, and drawing air through said chamber is effective to condense the lidocaine, verapamil, diltiazem, isometheptene, or lisuride vapor to form aerosol particles wherein the aerosol has an MMAD of less than 3 microns.

- 15. The kit according to claim 14, wherein the heat for heating the substrate is generated by an exothermic chemical reaction.
- 16. The kit according to claim 15, wherein said exothermic chemical reaction is oxidation of combustible materials.
- 17. The kit according to claim 14, wherein the heat for heating the substrate is generated by passage of current through an electrical resistance element.
- 18. The kit according to claim 14, wherein said substrate has a surface area dimensioned to accommodate a therapeutic dose of lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition in said coating.

Attorney Docket No.: 00030.03CON

Express Mail No.: ER 447 856 410 US

19. The kit according to claim 12, wherein a peak plasma concentration of lidocaine, verapamil, diltiazem, isometheptene, or lisuride is obtained in less than 0.1 hours after delivery of condensation aerosol to the pulmonary system.

20. The kit of claim 12, further including instructions for use.